This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Shionogi Company Limited. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Tsuguo Miyauchi: Innovator in Monoclonal Antibody Development
Introduction
Tsuguo Miyauchi is a prominent inventor based in Toyonaka, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has the potential to impact the treatment of various medical conditions.
Latest Patents
Miyauchi holds a patent for a monoclonal antibody against Nav1.7. The objective of this invention is to provide a novel monoclonal antibody that can be utilized for treating or preventing pain and pruritus. The patent discloses a monoclonal antibody or its antibody fragment, characterized by specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. This innovation represents a significant advancement in therapeutic options for patients suffering from pain-related conditions.
Career Highlights
Tsuguo Miyauchi is associated with Shionogi Company Limited, where he continues to work on groundbreaking research and development projects. His expertise in monoclonal antibodies has positioned him as a key figure in the biotechnology sector.
Collaborations
Miyauchi collaborates with notable colleagues, including Tatsuya Takahashi and Sosuke Yoneda. Their combined efforts contribute to the advancement of innovative solutions in the field of medicine.
Conclusion
Tsuguo Miyauchi's work in developing monoclonal antibodies showcases his dedication to improving healthcare through innovation. His contributions are paving the way for new treatments that can significantly enhance patient quality of life.